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Abstract
Introduction: The HPTN 071 (PopART) trial evaluated the impact of an HIV combination prevention package that included
“universal testing and treatment” on HIV incidence in 21 communities in Zambia and South Africa during 2013-2018. The pri-
mary study endpoint was based on the results of laboratory-based HIV testing for> 48,000 participants who were followed
for up to three years. This report evaluated the performance of HIV assays and algorithms used to determine HIV status and
identify incident HIV infections in HPTN 071, and assessed the impact of errors on HIV incidence estimates.
Methods: HIV status was determined using a streamlined, algorithmic approach. A single HIV screening test was performed
at centralized laboratories in Zambia and South Africa (all participants, all visits). Additional testing was performed at the
HPTN Laboratory Center using antigen/antibody screening tests, a discriminatory test and an HIV RNA test. This testing was
performed to investigate cases with discordant test results and confirm incident HIV infections.
Results: HIV testing identified 978 seroconverter cases. This included 28 cases where the participant had acute HIV infection
at the first HIV-positive visit. Investigations of cases with discordant test results identified cases where there was a participant
or sample error (mixups). Seroreverter cases (errors where status changed from HIV infected to HIV uninfected, 0.4% of all
cases) were excluded from the primary endpoint analysis. Statistical analysis demonstrated that exclusion of those cases
improved the accuracy of HIV incidence estimates.
Conclusions: This report demonstrates that the streamlined, algorithmic approach effectively identified HIV infections in this
large cluster-randomized trial. Longitudinal HIV testing (all participants, all visits) and quality control testing provided useful
data on the frequency of errors and provided more accurate data for HIV incidence estimates.
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1 | INTRODUCTION
Universal testing and treatment (UTT) for HIV prevention is
an important component of HIV prevention programmes [1,2].
The HIV Prevention Trials Network (HPTN) 071 (PopART)
trial, the largest HIV prevention trial performed to date, inves-
tigated whether UTT and other known effective prevention
strategies could reduce HIV incidence on a population level
[3]. HPTN 071 (PopART) was conducted in 21 urban and
peri-urban communities in South Africa and Zambia. The study
included two intervention arms (Arms A and B) and a stan-
dard-of-care arm (Arm C). Arms A and B included annual
home visits with HIV counselling, HIV rapid testing and sup-
port for HIV-infected individuals, including linkage to HIV care
and antiretroviral treatment (ART), support for ART adher-
ence and other prevention services [4]. ART was initiated at
the community health centre at any CD4 cell count (Arm A),
or according to local guidelines (Arm B). The impact of the
study interventions was measured in a randomly sampled Pop-
ulation Cohort (PC). The PC enrolled> 48,000 adults aged 18
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to 44 years; 71% were women. Participants were followed for
up to three years. The primary study endpoint was HIV
incidence after the first intervention year. HIV incidence was
reduced by 30% in communities where ART was
provided according to the local guidelines (Arm B vs. C), but
was not significantly reduced in communities with UTT (Arm
A vs. C) [3].
HIV incidence determination in community-randomized tri-
als presents unique challenges because of the large number of
participants and samples needed for study assessments. To
address these challenges, customized approaches were used
for sample and data management, HIV testing and determina-
tion of HIV status. This report describes the methods that
were used to identify incident HIV infections in the trial, and
the results obtained. This included identification and charac-
terization of acute and seropositive incident infections and
analysis of the performance of HIV screening assays included
in the testing algorithms. HIV incidence assessments can be
distorted by errors in participant and sample identification
(mixups). Determination of HIV status for all PC participants
at all visits allowed us to estimate the frequency of those
errors and assess the potential impact of those errors on the
accuracy of study results.
2 | METHODS
2.1 | Sample collection, processing and shipping
Samples and data were obtained from PC participants at
baseline (PC0) and annual follow-up visits (PC12, PC24 and
PC36) (2013-2018). At each visit, participants were offered
HIV rapid testing, and a 10-mL blood sample was collected
for laboratory-based HIV testing. This report includes results
from only laboratory-based testing; performance of point-of-
care HIV rapid testing are reported elsewhere [5]. The Labo-
ratory Data Management System was used to track samples
throughout the study. Plasma samples were frozen at 80°C
within 8 hours of collection. In South Africa, blood samples
were processed at a centralized laboratory (SUN Immunology
Laboratory; Cape Town) and were tested at the NHLS Labo-
ratory (Tygerberg Hospital, Cape Town). In Zambia, blood
samples were processed at one of the five regional laborato-
ries or a central laboratory (Zambart Central Laboratory;
Lusaka) and were tested at the Zambart Central Laboratory.
Plasma aliquots from all visits were shipped from the in-coun-
try central laboratories to the HPTN Laboratory Center (LC,
Johns Hopkins University, Baltimore, MD, USA). A subset of
the samples was tested at the LC using pre-specified testing
algorithms.
2.2 | Laboratory assays
Five assays were used to determine HIV status (Supplemental
File 1). Testing was performed at in-country laboratories using
a 4th-generation HIV test (the CE marked ARCHITECT HIV
Ag/Ab COMBO test [Architect]). The LC performed the Archi-
tect test (cleared by the United States FDA); a second 4th-
generation test (the GS HIV Combo Ag/Ab EIA [BioRad], per-
formed during PC0, PC12, and PC24); a 5th-generation test
(the BioPlex 2200 HIV Ag/Ab assay [BioPlex], performed dur-
ing PC36); a discriminatory HIV test (Geenius HIV-1/2
Supplemental assay [Geenius]); and an HIV RNA test (Abbott
RealTime HIV-1 Viral Load assay [HIV RNA]; validated dilution
method, limit of quantification: 400 copies/mL). Selected sam-
ples were tested with both the BioRad and BioPlex assays. To
streamline testing, samples were tested once with the Archi-
tect test at all three laboratories.
2.3 | Quality control testing
Architect test results from in-country and LC testing were
electronically transferred to the statistical and data manage-
ment center (SDMC), and laboratory personnel were blinded
to study arm throughout the trial. All samples with a reactive
in-country Architect test result were tested at the LC with
the BioRad test (PC0, PC12 and PC24) or the BioPlex test
(PC36); a random subset (~10%) of the samples with a non-
reactive in-country Architect test result were tested at the LC
using the same assay (Architect test) (Figure 1).
2.4 | Determination of within-visit HIV status
The results of in-country testing and QC testing were com-
pared to identify samples with discordant results (reactive/
non-reactive). Additional testing was performed at the LC for
those samples (Figure 1). Within-visit HIV status was classified
as NEG (HIV uninfected), POS (HIV infected), or INC (incon-
clusive; Supplemental File 2).
2.5 | Determination of across-visit HIV status
HIV test results were compared across study visits to iden-
tify samples that required additional testing. This included
cases that had a NEG visit followed by a visit with a reactive
test (potential seroconverter), cases that had a POS or INC
visit followed by a visit with a non-reactive test (potential
“seroreverter,” indicating possible participant/sample mixups)
and other cases with discrepant test results. Across-visit HIV
status (HIV status based on the analysis of samples from
longitudinal study visits) was determined using in-country
and LC test results. Cases were provisionally classified as
HIV POS (HIV infected at all visits), HIV NEG (HIV unin-
fected at all visits), potential seroconverter, potential serore-
verter, or to be determined (across-visit status unclear due
to missing and/or discrepant HIV test results). For serocon-
verter and seroreverter cases, additional testing was per-
formed at selected study visits to confirm the change in HIV
infection status (Figure 2). In confirmed seroconversion
cases, samples collected at the last NEG visit were also
tested with the HIV RNA test to determine if the participant
had acute infection at that visit. Samples were classified as
having acute infection (POS ACUTE) if the Geenius test was
negative and HIV RNA was detected. Additional visits with
acute HIV infection were identified at study entry and at
end-of-study visits during the evaluation of samples with dis-
cordant test results.
2.6 | Endpoint adjudication
Within-visit and across-visit HIV status were determined at
the LC (by manual review of test results) and at the SDMC
(using computerized algorithms). Cases that had concordant
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LC and SDMC HIV status determinations were not reviewed
further. All the remaining cases were reviewed by a Virology
Endpoint Adjudication Committee (VEAC) that included two
virologists from the LC and three external virologists (Supple-
mental File 2).
2.7 | Evaluation of errors due to participant or
sample mixups
We evaluated the frequency of errors due to participant or
sample mixups by comparing within-visit HIV status for partic-
ipants who had paired HIV status results from consecutive
visits in three time intervals: PC0-PC12, PC12-PC24 and
PC24-PC36. Statistical methods used to derive error rates
and the probability of true incident cases are shown in Sup-
plemental File 3. Briefly, for this analysis, the error rate, m,
represents probability that test results from a visit do not
belong to the designated study participant. The error rate was
evaluated by determining the proportion of cases where the
within-visit HIV status changed from POS to NEG (bpPNÞ,
where bp1andbp2 represent the observed prevalence of a POS
within-visit status at the first or second of the paired visits
respectively:
m ¼ 1
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1 p^PN
p^1 1 p^2ð Þ
s
After accounting for the probability of errors, the probabil-
ity, bd, of a true incident infection among those who were HIV
uninfected at the first visit where both samples came from
the same study participant is as follows:
d^ ¼ p^2  p^1
1 p^1ð Þ
2.8 | Informed consent
Written informed consent was obtained from all PC partici-
pants [3]. Ethical approval for the trial was provided by
Figure 1. Determination of within-visit HIV status. Within-visit HIV status was classified as NEG (HIV uninfected), POS (HIV infectesssd), or
INC (inconclusive; HIV status not determined). Results of in-country testing and quality control (QC) testing at the HPTN Laboratory Center
(LC) were compared to identify samples with discordant test results (reactive/non-reactive). (A) shows the QC testing algorithm and (B) shows
the testing algorithm for samples with discordant site/LC test results. HIV assays: ARCHITECT HIV Ag/Ab COMBO Test (Architect test), GS HIV
Combo Ag/Ab EIA (BioRad test), BioPlex 2200 HIV Ag-Ab Assay (BioPlex test), Geenius HIV-1/2 Supplemental Assay (Geenius test), and Abbott
RealTime HIV-1 Viral Load Assay (HIV RNA test).
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committees at London School of Hygiene and Tropical Medi-
cine, University of Zambia, and Stellenbosch University.
3 | RESULTS
3.1 | Samples used for analysis
Overall, 48,301 participants were enrolled in the PC. HIV sta-
tus was evaluated in 47,470 PC participants; 831 (1.7%) par-
ticipants had no samples available for testing (missing HIV
status). Table 1 shows the number of samples tested for each
enrolment group in each survey year (total 120,164 samples
tested). Overall, 278 (0.23%) of the 120,154 samples had dis-
cordant test results; there was no significant difference in the
frequency of discordant test results by age, sex, study country
or study arm (data not shown).
3.2 | Determination of within-visit HIV status for
samples that had a non-reactive or missing in-country
test result
Architect test results were obtained in-country for 119,270
(99.3%) of the 120,164 samples collected. The remaining 894
samples had no aliquot available for in-country testing or did not
have a test result. The in-country Architect test was non-reactive
for 92,186 (77.3%) of the 119,270 samples tested. The same
assay was performed at the LC for 10,731 (11.6%) of the 92,186
samples; this included samples that were randomly selected for
QC testing (Figure 1A) and samples that had additional testing
performed at the LC to determine across-visit HIV status. The LC
Architect test was non-reactive for 10,680 (99.5%) of the 10,731
samples, confirming the results of the in-country test. Those sam-
ples were classified as NEG and were not analysed further unless
the participant had a change in HIV status across visits.
In the remaining 51 cases (0.5%), results of the two Architect
tests were discordant (non-reactive in-country test, reactive LC
test). Those samples were tested at the LC with the BioRad or
BioPlex test, the Geenius test and the HIV RNA test (Supplemen-
tal File 4A). HIV status was not determined for one sample
(classified as INC). Further testing of the remaining 50 samples
confirmed that 27 were HIV negative and 23 were HIV positive.
The discrepancy between S/CO values obtained at the site and
LC suggest that the majority of these were sample or data
mixups (Supplemental File 4B). The analysis also indicated that
triplicate testing with the Architect test for samples with S/CO
ratios ≥ 1 (as recommended by the manufacturer) would not
have resolved most of the discrepancies (Supplemental File 4C).
3.3 | Determination of within-visit HIV status for
samples that had a reactive in-country test result
Overall, 27,084 (22.7%) of the 119,270 samples had a reac-
tive in-country Architect test; 26,972 (99.6%) of those
Figure 2. Confirmation of seroconverter and seroreverter cases. The figure shows the testing strategy used to confirm seroconverter and
seroreverter cases. NEG, negative; POS, positive.
Table 1. Number of samples analysed by enrolment cohort and
survey year
Enrolment
Annual survey
Totalgroup PC0 PC12 PC24 PC36
PC0 37,320 22,925 20,028 20,029 100,302
PC12N -- 4,844 3,415 3,362 11,621
PC24N -- -- 4,650 3,591 8,241
TOTAL 37,320 27,769 28,093 26,982 120,164
Participants were enrolled in the HPTN 071 Population Cohort (PC)
during a baseline survey (PC0) and during annual surveys conducted
one or two years later (PC12N and PC24N respectively; total
enrolled: 48,301). Samples were collected at baseline (PC0) and dur-
ing three annual surveys (PC12, PC24 and PC36) from participants
who consented to sample collection (total participants with at least
one sample available: 47,470); 831 cases had no sample available from
any study visit (e.g. no study visit, participant refused sample collec-
tion, unsuccessful blood draw). The table shows the number of sam-
ples analysed from each of the four annual surveys (PC0, PC12, PC24
and PC36) from each enrolment group (PC0, PC12N and PC24N).
Samples from enrolment visits are shown in bold text (total number of
enrolment samples: 46,814).
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samples were tested with a second HIV screening test at the
LC (BioRad or BioPlex test; Figure 1). A reactive BioRad or
BioPlex test was obtained for 26,745 (99.2%) of the samples.
The remaining 227 samples (0.8%) had discordant test
results (reactive in-country Architect test, non-reactive LC
BioRad or BioPlex test); those samples were tested at the
LC with the Geenius test and HIV RNA test (Figure 1B).
Overall, 206 (90.7%) of the 227 samples were confirmed to
be from HIV-uninfected individuals (Supplemental File 5A).
The remaining 21 samples included eight that were con-
firmed to be HIV positive (including three acute samples) and
13 with inconclusive HIV status. Additional testing was per-
formed to evaluate the reasons for the discordant test
results. That analysis indicated that some discordant results
reflected laboratory errors (sample or data mixups; testing or
data errors), while others were likely explained by assay vari-
ability (Supplemental File 5B).
Sixty additional samples had reactive results with the LC
Architect test and the LC BioRad or BioPlex test, but were
confirmed to be from HIV-uninfected individuals (data not
shown). Those cases, which had false reactive results with two
different screening tests, were identified during evaluation of
possible seroconverter or seroreverter cases.
3.4 | Determination of across-visit HIV status
Across-visit HIV status was provisionally determined for each
participant by analysing test results from longitudinal study
visits; a pre-determined plan was used to identify cases that
required additional adjudication to determine across-visit HIV
status, to determine the timing of seroconversion events, and
to identify participants who had an acute HIV infection visit
(see Methods). Overall, 369 (0.76%) of the 48,301 cases were
referred for VEAC review. The final across-visit status chan-
ged in 69 (28.7%) of those cases and two cases that were not
referred for review (Supplemental File 2).
3.5 | Identification of seroconverter cases
After accounting for the 831 cases with missing HIV status,
16 ND cases, 213 seroreverter cases and 10,051 cases where
the participant was HIV infected at enrolment, 37,190 cases
remained where the participant was HIV uninfected at enrol-
ment; 26,498 (71.3%) of these cases had at least one sample
tested from a subsequent study visit. Potential seroconverter
events were identified when a visit classified as NEG was fol-
lowed by a visit where the in-country test result or the LC
QC test result was reactive; additional testing was performed
at the LC in these cases (Figures 1B and 2). All potential sero-
converters were further classified based on the timing of the
last NEG and first POS visits (e.g. SC0-12, for the last NEG
visit at PC0 and the first POS visit at PC12). Overall, 978
seroconverter cases were identified after adjudication
(Table 2); 752 (77%) of the seroconverters had detectable
HIV RNA at the first POS visit (two did not have a viral load
test at this visit). The median HIV viral load at the first POS
visit in these 752 cases was 14,435 copies/mL (range: 400
to> 16 million). The percentage of seroconverter cases with
viral loads < 400 copies/mL increased over time (25% at
PC12, 30% at PC24, 33% at PC36; 29% overall, all three
visits).
Table 2. Final across-visit HIV status
HIV status
Number
of cases
Percentage
of cases
Across-visit HIV status
Missing 831 1.72
Negative all visits 36,212 74.97
Positive all visits 10,051 20.81
Serorevertera 213 0.44
Not determined 16 0.03
Seroconverter 978 2.03
Total 48,301
Seroconverter type
Primary endpoint NEG at PC12b 505
Primary endpoint – no status at PC12b 48
Acute infection at first POS visitc 28
Seroconverter
timing
Number of
cases
Percentage of
seroconverters
PC0-12 360 36.81
PC0-24 67b 6.85
PC0-36 46b 4.70
PC12-24 225 23.01
PC12-36 57 5.83
PC24-36 223 22.80
TOTAL 978
The table shows the final across-visit HIV status for 48,301 partici-
pants enrolled in the HPTN 071 Population Cohort. Of these, 831
had no samples available for analysis (missing) and 16 did not have
HIV status determined due to missing and/or inconclusive HIV test
results. HIV status was determined on at least one visit for the
remaining 47,454 participants. Classifications included: HIV NEG (HIV
negative at all visits with an HIV status); HIV POS (HIV positive at all
visits with an HIV status; in some of these cases, the participant had
acute HIV infection at the first HIV-positive visit); seroreverter (con-
firmed HIV-positive visit followed by a confirmed HIV-negative visit);
seroconverter (confirmed HIV-negative visit followed by a confirmed
HIV-positive visit) (see Supplemental Table 2).
aIn all 213 seroreverter cases, participants had a positive Geenius test
before testing negative for HIV infection; there were no seroreversion
cases where the only HIV-positive visit was a visit with acute HIV
infection. The overall rate of seroreversion events among the subset
of cases with HIV status determined at two or more visits was 0.64%.
Seroreversion was not associated with sex or study arm; a slightly
higher frequency of seroreversion cases was observed in Zambia com-
pared to South Africa (0.75% vs. 0.47%), and among older participants
(0.78% in those age > 24 vs. 0.41% in those ages 18 to 24)”; bSero-
converters who were HIV uninfected at the PC12 visit were included
in the primary study endpoint analysis. This included 225 cases classi-
fied as SC12-24, 223 cases classified as SC24-36, and 57 cases classi-
fied as SC12-36. In 113 cases classified as SC0-24 or SC0-36,
participants did not have HIV status determined at PC12 due to a
missed study visit or no sample collected; 48 of these cases con-
tributed to the primary endpoint using statistical imputation methods
(see Methods); cParticipants who had acute HIV infection at enrol-
ment were not classified as seroconverters. Participants who were
HIV NEG at PC0 and had acute HIV infection at PC12 were classified
as seroconverters, but were not included in the primary endpoint
analysis.
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3.6 | Evaluation of cases with acute HIV infection
Twenty-eight cases of acute infection were identified (Table 2).
Twenty-two of these cases had a subsequent visit with docu-
mented HIV seroconversion (reactive Geenius test); in the
other six cases, acute infection was detected at the last study
visit. A detailed description of these cases is presented in Sup-
plemental File 6.
3.7 | Evaluation of the potential impact of
sample/data mixups on HIV incidence estimation
Overall, 33,408 cases had HIV test results from at least two
study visits; 213 (0.64%) of those cases had results that indi-
cated an error or specimen mixup (seroreverter cases). In
154 of the 213 cases, the participant had a POS status at
enrolment; those cases were never considered eligible for the
incidence analysis. In the remaining 59 cases, the participant
had a NEG status at enrolment, and had a sample from a
subsequent visit with confirmed HIV infection (Supplemental
File 7). Those 59 cases were provisionally classified as sero-
conversion events; however, the classification was later chan-
ged from seroconverter to seroreverter, because a sample
from a later study visit was confirmed to be HIV negative.
Those 59 cases included 33 cases where the participant had
a NEG status at PC12; those 33 cases would have been
included as primary endpoint events if the seroreversion
event was not detected.
While seroreverter cases provided clear evidence of sam-
ple/participant mixups, this type of error could have
occurred in other cases without being detected, and could
have led to misclassification of seroconverter cases (e.g. if
the sample used to determine HIV status at the first POS
visit was from a different participant and the participant
had no subsequent study visit). We used data from the
seroreversion cases to estimate the impact of these errors
on the accuracy of identification of incident infections
(Table 3, Supplemental File 3). In this analysis, data from
paired sequential study visits were analysed in three differ-
ent time intervals. We identified 47 seroreversion events
(errors) in the interval PC0-12 (0.21%), 64 seroreversion
events in the interval PC12-24 (0.31%) and 75 serorever-
sion events in the interval PC24-36 (0.32%). In the first
interval (PC0-12), there were 384 apparent incident cases
(i.e. cases where within-visit HIV status changed from NEG
to POS; 2.20% of cases analysed); 24 of those cases were
classified as seroreverter cases, because the participant had
a NEG within-visit HIV status at a subsequent visit. After
removing those 24 cases, 360 of the 384 cases remained
classified as seroconverters (observed incident cases; 2.03%
of cases analysed). Using the observed rate of mixups to
estimate the overall (unobserved) error rate, the estimated
frequency of true incident infections in this time interval
was 1.90% (corrected incidence rate). The same approach
was used to calculate the observed (uncorrected) and cor-
rected number of incident cases in each time interval. In
each of the three time intervals, exclusion of seroreversion
cases removed at least half of the potential seroconverter
cases that were likely to represent participant or sample
errors (Table 3).
4 | DISCUSSION
This report describes the methods used to determine HIV sta-
tus and identify incident infections in the HPTN 071 (PopART)
trial. The size of this trial (48,301 participants followed for up to
three years; >120,000 samples tested) presented challenges in
sample and data management. A streamlined approach was
used to reduce the cost, effort and complexity of HIV testing.
Customized data management procedures were used to reduce
the frequency of clerical errors. An external adjudication com-
mittee reviewed > 300 cases with complex test results. Across-
visit HIV status was determined in all but 16 cases. Limitation
of testing for many samples to a single HIV screening test had a
minimal impact on study results.
In a previous community-randomized study, the primary
HIV incidence endpoint was determined by analysing samples
collected in a cross-sectional survey of > 46,000 individuals
[6]. In that study, the testing algorithm used for cross-sec-
tional HIV incidence estimation included viral load as a bio-
marker for non-recent infection [7]; low viral load is also used
as a biomarker for non-recent infection in an algorithm that is
widely used for cross-sectional HIV incidence estimation in
surveillance studies [8,9]. Further studies are needed to
assess the performance of these algorithms in settings where
ART is initiated early in HIV infection since individuals with
recent infection who are virally suppressed from ART would
be misclassified as having non-recent infection.
Overall, 978 seroconverter cases were identified; 553 of
these cases were used for the primary HIV incidence analysis
[3]. The viral loads were < 400 copies/mL in 29% of all sero-
converter cases. In these cases, HIV infection may have been
diagnosed in the community between study visits and the par-
ticipant may have initiated ART before the seroconversion
was documented by study testing; in some cases, the partici-
pant may have been virally suppressed in the absence of ART.
The frequency of low viral load seroconverter samples
increased over time, suggesting an increase in earlier diag-
noses and ART initiation over the course of the study.
Twenty-eight participants had acute HIV infection at the first
HIV-positive visit. In four cases, the viral load was <400 copies/
mL at the acute visit. Since the 978 seroconversion events were
likely distributed evenly over the year preceding the first HIV-
positive visit, we would expect that some seroconverter events
would be detected during the acute infection period (e.g. within
one week of HIV infection) and that a portion of those cases
would be detected only 1-2 days after infection, at a time when
viral load might be low. The sensitivity for detecting acute infec-
tions was similar for the three laboratory-based antigen/anti-
body HIV screening tests (Architect, BioRad, BioPlex). The 5th-
generation test (BioPlex) identified only 25% of the acute sam-
ples as positive for HIV antigen only. ART initiation during acute
infection can suppress viraemia and HIV antibody expression;
loss of HIV antibodies (seroreversion) has been described in
some cases [10]. In HPTN 071, it is unlikely that participants
would have initiated ART during the acute phase of HIV infec-
tion since HIV testing offered at home visits was performed
using 3rd-generation HIV rapid tests. Furthermore, the labora-
tory-based testing described in this report did not identify any
seroreversion cases where an acute infection visit was followed
by a confirmed HIV-negative visit.
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This report included comparison of Architect test results
obtained in-country and at the HPTN LC for >10,000 sam-
ples. Two non-reactive results were obtained in 10,680
(99.5%) of these cases. We evaluated cases with discordant
Architect tests, and cases where the in-country Architect test
and LC BioRad/BioPlex tests were discordant. Investigation
indicated that some of these cases likely represented labora-
tory errors (aliquot mixups, or sample/data errors). Other
cases involving participant or sample mixups were identified
by longitudinal testing (seroreverter cases). Longitudinal HIV
testing is not performed in most studies once an individual is
determined to be HIV infected [11]; therefore, most studies
will not detect these errors. These cases were relatively rare
in HPTN 071 (PopART), considering the size of the study
(0.4% of 47,470 cases evaluated). Seroreverter cases were
excluded from the analysis of HIV incidence. Using statistical
methods, the frequency of seroreverter cases was used to
estimate the possible number of undisclosed mixups that may
have resulted in incorrect identification of seroconverter
events or failure to identify seroconverter events. Statistical
analysis showed that exclusion of seroreverter cases from
HIV incidence analysis improved the accuracy of the inci-
dence estimate.
5 | CONCLUSIONS
This report demonstrates that the streamlined, algorithmic
approach was effective for identifying incident HIV infections
in this large community-randomized trial. The report also
demonstrates the utility of QC testing for investigation of dis-
cordant test results, the value of performing HIV testing for
all participants at all visits, removal of seroreverter cases and
the use of statistical methods for investigating the impact of
sample mixups on HIV incidence estimates increased the accu-
racy of HIV incidence estimates.
Table 3. Analysis of within-visit HIV status for paired visits to assess the impact of participant/sample mixups on reported HIV
incidence
First year of follow-up Second year of follow-up Third year of follow-up
Observed data pairsa
PC0, PC12
(N = 22,555) %
PC12, PC24
(N = 20,693) %
PC24, PC36
(N = 23,802) %
Negative (N?N) 17,401 77.15% 15,866 76.67% 18,159 76.29%
Positive (P?P) 4,723 20.94% 4,489 21.69% 5,305 22.29%
Possible seroconverter (N?P) 384 1.70% 274 1.32% 263 1.10%
Seroreverters (errors) (P?N) 47 0.21% 64 0.31% 75 0.32%
Estimated error rate (mb) 0.64% 0.92% 0.91%
Proportion infected, first visit (p1) 21.15% 22.00% 22.60%
Proportion infected, second visit (p2) 22.64% 23.02% 23.39%
Expected number of errors
(based on error ratec)
Seroconverter (N?P) 51 68 78
Negative (N?N) 175 227 257
Observed number of errors
(cases removed following adjudication)
Seroconverter (N?P) 24 49 40
Negative (N?N) 26 21 33
Observed (uncorrected)
proportion incidentd
384/
(17,401 + 384)
2.20% 274/
(15,866 + 274)
1.72% 263/
(18,159 + 263)
1.44%
Reported proportion incidente
(removing observed errors)
(384-24)/
(17,401-26 + 384-24)
2.03% (274-49)/
(15,866-21 + 274-49)
1.40% (263-40)/
(18,159-33 + 263-40)
1.22%
Probable true proportion incidentf
(based on paired final HIV results)
(384-51)/
(17,401-175 + 384-51)
1.90% (274-68)/
(15,866-227 + 274-68)
1.30% (263-78)/
(18,159-257 + 263-78)
1.02%
aData indicate the number of participants with samples collected at two consecutive study visits (PC0 and PC12; PC12 and PC24; PC24 and
PC36). N?N: participants classified as HIV NEG at both visits; P?P: participants classified as HIV POS at both visits; N?P: participants classified
as HIV NEG at the first visit and HIV POS at the subsequent visit; P?N: participants classified as HIV POS at the first visit and HIV NEG at the
subsequent visit (these cases represent observed errors in participant or sample identification at one or both study visits); bThe symbol, m, repre-
sents the estimated error rate (the estimated proportion of cases where within-visit HIV status was incorrect at one or both visits due to a partic-
ipant or sample mixup); cThese estimates are based on the estimated error rate (m); dThis shows the proportion of incident cases and incidence
rate observed without excluding seroreverter cases (observed errors); eThis shows the proportion of incident cases and incidence rate after
excluding seroreverter cases (observed errors); fThis shows the probable (true) proportion of incident cases and incidence rate based on analysis
of paired within-visit HIV status results, adjusting for unobserved errors due to participant or sample mixups.
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